Comparing the noninfectious adverse effects of two rabbit anti-thymocyte globulin immunosuppression in kidney transplantation: a multicenter, retrospective study [0.03%]
兔抗胸肌球蛋白免疫抑制在肾脏移植中的非感染不良反应的多中心回顾性研究比较
Mojtaba Shafiekhani,Ayda Esmaeili,Fatemeh-Sadat Emami et al.
Mojtaba Shafiekhani et al.
Background: Rabbit anti-thymocyte globulin (rATG) is widely used for induction immunosuppression in kidney transplantation; however, its administration carries some adverse effects. This study aimed to detect the incidenc...
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials [0.03%]
生物类似药及其参照生物药在强直性脊柱炎中疗效、安全性和免疫原性的系统评价和meta分析
Chin Hang Yiu,Chung Hin Or,Khalid Almutairi et al.
Chin Hang Yiu et al.
Introduction: This systematic review and meta-analysis aimed to compare the efficacy, safety, and immunogenicity of biosimilars and reference biologics (adalimumab, etanercept, infliximab) in the treatment of ankylosing s...
Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergence [0.03%]
全球生物类似药审批监管格局的发展：目前面临的挑战及机遇融合点
Elif Car,Liese Barbier,Isabelle Huys et al.
Elif Car et al.
Introduction: Biosimilars promote price competition, improving affordability and access to biologics without compromising on quality, efficacy, and safety. Biosimilar approvals initially followed a cautious approach, with...
The potential of factor XII inhibitors in preventing hereditary angioedema attacks [0.03%]
因子XII抑制剂预防遗传性血管水肿发作的潜力
James K Y Hooi,Jane C Y Wong,Philip H Li
James K Y Hooi
Introduction: Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of subcutaneous and/or submucosal swelling (angioedema). Current HAE-specific medications primarily focus on either ...
Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis [0.03%]
中等剂量他汀治疗合并心血管危险因素患者的依折麦布疗效和安全性的系统评价和meta分析
Mayank Jha,Siddharth Pravin Agrawal,Darshilkumar Maheta et al.
Mayank Jha et al.
Introduction: This systematic review and meta-analysis evaluated the lipid-lowering efficacy and safety of evolocumab in statin-treated patients at high cardiovascular risk, focusing on changes in LDL-C, TG, ApoB, HDL-C, ...
The "totality of evidence" and "extrapolation" of SB17, a ustekinumab biosimilar [0.03%]
关于ustekinumab类似药SB17的“全部证据”和“推论”
Jae Hee Cheon,Byong Duk Ye,Alessandro Armuzzi et al.
Jae Hee Cheon et al.
Introduction: SB17 is a ustekinumab (UST) biosimilar targeting interleukin-12/23 for treating immune-medicated inflammatory diseases (IMIDs). The development of UST biosimilars like SB17 May help address the high cost of ...
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis? [0.03%]
Guselkumab抑制IL-23的双重机制对溃疡性结肠炎有帮助吗？
Sheila A Doggrell
Sheila A Doggrell
Introduction: Ulcerative colitis (UC) includes a dysregulated immune response. The conventional therapy includes immunosuppressants, and biologics targeting inflammatory mediators, but these are often inadequate, or subje...
An evaluation of recaticimab for the treatment of hypercholesterolemia [0.03%]
评估 Recaticimab 治疗高胆固醇血症的效果
Xuan L Tang,Amanda J Hooper,John R Burnett
Xuan L Tang
Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, by preventing the degradation of LDL receptors, either through interference in the binding of PCSK9 to LDL receptors or through silencing of ...
An evaluation of patritumab deruxtecan for the treatment of EGFR-mutated non-small cell lung cancer [0.03%]
德鲁替康帕妥珠单抗治疗EGFR突变型非小细胞肺癌的评估研究
Barliz Waissengrin,Karen L Reckamp
Barliz Waissengrin
Introduction: Epidermal growth factor receptor (EGFR) mutations represent targetable alterations in non-small cell lung cancer (NSCLC). The treatment landscape in the frontline setting for patients with advanced EGFR-muta...
The potential role of biosimilars in healthcare sustainability in Latin America [0.03%]
生物类似药在拉丁美洲医疗保健可持续性中的潜在作用
Rony Schaffel,Paul Cornes,Manuel A Espinoza et al.
Rony Schaffel et al.
Introduction: Latin American (LatAm) countries face significant increases in healthcare expenditure, driven largely by population growth and aging, and the rising prevalence of cancer and other chronic diseases. Growing d...